Alnylam Pharmaceuticals Inc
ALNY
Market Cap$34.4B
Close$
Earnings Call Q2 2024
August 1, 2024 - AI Summary
Alnylam Pharmaceuticals reported a strong second quarter with a 34% year-over-year growth in global net product revenues, primarily driven by a 37% growth in their TTR franchise.
The positive top-line results from the HELIOS-B Phase 3 study of vutrisiran in ATTR cardiomyopathy were announced, showing significant improvements in cardiovascular outcomes and mortality benefits compared to placebo. This positions vutrisiran as a potential new standard of care in ATTR cardiomyopathy.
The company plans to host a TTR Investor Day on October 9th to highlight their leadership in ATTR amyloidosis and discuss efforts to optimize the launch of AMVUTTRA in ATTR cardiomyopathy.
Exclusive for Stockcircle Pro members
Sign up
$160.69
40% downside
Current Fair Value
40% downsideOvervalued by 40% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $34.40 Billion |
|---|---|
| Enterprise Value | $34.81 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-3.52 |
| Beta | 0.38 |
| Outstanding Shares | 126,733,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -465.63 |
|---|---|
| PEG | 495.97 |
| Price to Sales | 14.89 |
| Price to Book Ratio | -267.99 |
| Enterprise Value to Revenue | 14.85 |
| Enterprise Value to EBIT | 339.13 |
| Enterprise Value to Net Income | -478 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | -447.57 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Alnylam Pharmaceuticals Inc
CEO: John Maraganore